R&G PharmaStudies Co., Ltd. (SHE:301333)
China flag China · Delayed Price · Currency is CNY
62.13
+2.05 (3.41%)
Mar 27, 2026, 4:00 PM EDT

R&G PharmaStudies Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
5,9115,6664,7566,1904,940-
Market Cap Growth
17.34%19.12%-23.17%25.30%--
Enterprise Value
4,2153,9603,1244,5643,498-
Last Close Price
62.1359.5549.8363.8950.84-
PE Ratio
43.4541.3933.9238.0943.55-
Forward PE
35.9133.1325.30---
PS Ratio
6.956.666.398.587.75-
PB Ratio
2.992.872.593.533.10-
P/TBV Ratio
3.173.042.753.583.14-
P/FCF Ratio
62.2759.6835.2935.8545.06-
P/OCF Ratio
51.7649.6130.7332.1537.87-
EV/Sales Ratio
4.954.654.206.335.49-
EV/EBITDA Ratio
26.4525.2124.2629.6931.68-
EV/EBIT Ratio
31.2229.3325.8134.8133.97-
EV/FCF Ratio
44.4141.7223.1826.4331.90-
Debt / Equity Ratio
0.020.020.040.010.010.03
Debt / EBITDA Ratio
0.280.280.510.050.130.08
Debt / FCF Ratio
0.470.470.530.050.140.14
Net Debt / Equity Ratio
-0.86-0.86-0.93-0.97-0.94-0.80
Net Debt / EBITDA Ratio
-10.84-10.84-13.23-11.03-13.64-2.59
Net Debt / FCF Ratio
-17.94-17.94-12.65-9.82-13.74-4.60
Asset Turnover
0.360.360.340.370.501.01
Inventory Turnover
8.948.948.048.338.3610.43
Quick Ratio
5.425.424.736.206.252.35
Current Ratio
5.605.604.886.386.452.58
Return on Equity (ROE)
7.26%7.26%7.90%9.73%11.24%25.91%
Return on Assets (ROA)
3.56%3.56%3.43%4.14%5.03%11.35%
Return on Invested Capital (ROIC)
49.32%59.54%113.70%159.47%104.63%136.45%
Return on Capital Employed (ROCE)
6.70%6.70%6.40%7.50%6.40%24.60%
Earnings Yield
2.32%2.42%2.95%2.63%2.30%-
FCF Yield
1.61%1.68%2.83%2.79%2.22%-
Dividend Yield
0.26%-0.32%0.31%0.31%-
Payout Ratio
8.61%8.61%20.24%3.58%--
Buyback Yield / Dilution
-0.36%-0.36%0.64%-16.78%-14.43%0.38%
Total Shareholder Return
-0.10%-0.36%0.96%-16.46%-14.12%0.38%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.